Palomino Laboratories (PALX) Common Equity (2022 - 2025)

Palomino Laboratories' Common Equity history runs 4 years deep, the most recent figure standing at $8.1 million for Q4 2025.

• In Q4 2025, Common Equity rose 44335.15% year-over-year to $8.1 million; the TTM figure through Dec 2025 stood at $8.1 million (up 44335.15% YoY), while the FY2025 annual figure was $8.1 million, up 44335.15% from the prior year.
• Common Equity came in at $8.1 million for Q4 2025 at Palomino Laboratories, up from $7.3 million in the prior quarter.
• In the past five years, Common Equity ranged from a high of $8.1 million in Q4 2025 to a low of -$991653.0 in Q1 2025.
• A 4-year average of $1.1 million and a median of -$18306.0 in 2023 frame the typical range for Common Equity.
• On a YoY basis, Common Equity climbed as much as 87763.29% in 2025 and fell as far as 42008.41% in 2025.
• Palomino Laboratories' Common Equity stood at -$27804.0 in 2022, then jumped by 34.16% to -$18306.0 in 2023, then changed by 0.0% to -$18306.0 in 2024, then soared by 44335.15% to $8.1 million in 2025.
• According to Business Quant data, Common Equity over the past three periods registered $8.1 million, $7.3 million, and -$447236.0 for Q4 2025, Q3 2025, and Q2 2025 respectively.

Peer Comparison